Search

Copyright of Revista Medica del IMSS is the property of Direccion de Prestaciones Medicas - IMSS and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Subcorneal pustular dermatosis is a disease that has coalescent, laccid, recurrent pustules. We do not know everything about its etiology or pathogenesis; however, its autoimmune mechanism links it with neoplastic or immunologic diseases. First line treatment is dapsone. We describe the case of a classic subcorneal pustular dermatosis in a patient in who we could not use dapsone (sulpha drugs allergy), instead we prescribed prednisone and methotrexate, with good clinical evolution. [ABSTRACT FROM AUTHOR]

Background: Adverse drug reactions have different clinical expressions. The skin is an organ directly involved in the processes of pharmacokinetics and pharmacodynamics and is capable of expressing multiple reactions in response to different stimuli medicated. Objectives: To determine the prevalence of adverse drug reactions, to identify and to establish the associated morbidity and mortality as well as the most frequent reactions in hospitalized patients in the Dermatology service of the Specialties Hospital, West National Medical Center, Mexican Institute of Social Security. Material and method: A cross-sectional and retrospective analysis performed with patients hospitalized in the Dermatology service from January 1st, 2004 to December 31st, 2012 according to a non-probabilistic counting of consecutive cases. Results: Adverse drug reactions corresponded to 34.4% of patients hospitalized in the Dermatology service; 63% were female. The most common reaction was Brocq-Lyell syndrome (32%), followed by Stevens-Johnson syndrome (14%). The most frequent comorbidity was epilepsy (16.1%) and diabetes mellitus (15%); 24% of the patients died. Conclusions: Stevens-Johnson and Brocq-Lyell syndrome were found more frequently related with adverse drug reactions in Dermatology service of the Specialties Hospital, West National Medical Center, Mexican Institute of Social Security. [ABSTRACT FROM AUTHOR]

Stevens-Johnson syndrome, overlap syndrome Stevens-Johnson-toxic epidermal necrolysis and toxic epidermal necrolysis or Brocq-Lyell syndrome are uncommon diseases caused by drugs in the most of cases. Toxic epidermal necrolysis is a potentially fatal illness, which is characterized by extensive epidermal detachment combined with severe inflammation and denudation of the mucosal surfaces. Because of low incidence of toxic epidermal necrolysis, the treatment is controversial, however, withdrawing causal medication, nutritional and electrolytic balance support and control of infections are the key to better evolution of the patients. Intravenous immunoglobulin and cyclosporine A can be effective therapies when there are no contraindications for its use. [ABSTRACT FROM AUTHOR]

Psoriasis is a chronic inflammatory disease with a worldwide prevalence between 6 and 39% in moderate to severe forms. In European countries like Germany and England was identified that only one third of patients with moderate to severe forms will receive systemic management, this fact motivated to integrate into Europe an international consensus on treatment goals with the aim of providing support to the dermatologist by algorithms that serve as a therapeutic guide that allows you to gain control short and long term effects of this disease. The European group met to develop the definitions of severity of psoriasis, treatment goals for moderate to severe disease, and optimization options and / or therapeutic transition than a paper published in 2011 was obtained. In Mexico a working group of experts on biological therapy (GTEB), made up of 10 members and an extended group of 150 dermatologists' voters in the country for the purpose of issuing Mexico's position on the proposals of the European group was formed. In this document the findings of the Working Group of Experts on Biological Therapy in Mexico are listed.